Bionomics : presents at Biotech Showcase 2017

ABN 53 075 582 740

ASX ANNOUNCEMENT 9 January 2017 BIONOMICS TO FEATURE AT 2017 SAN FRANCISCO BIOTECH SHOWCASE

Bionomics Limited (ASX:BNO, OTCQX:BNOEF), a global, clinical stage biopharmaceutical company, advises that it will present a company update at Biotech Showcase™ 2017 on Wednesday 11 January, 2017 at 11.00am PST at the Hilton San Francisco Union Square.

The three-day event beginning today coincides with the 35th Annual JP Morgan Healthcare Conference and associated life sciences investment and partnering meetings.

The Biotech Showcase™ is expected to attract over 3,000 attendees, including over 300 presenting companies and over 550 investors. Bionomics' presentation will provide an overview of the Company's clinical programs including the key 2017 milestones:

• Positive BNC210 Phase 2 clinical trial results in Generalized Anxiety Disorder (GAD) patients reported 21 September 2016.

• The ongoing Phase 2 PTSD trial enabling exploration of both partnership options and pathways for broader BNC210 development.

• Anticipated Phase 1 trial results from cancer stem cell targeting drug candidate BNC101 in patients with metastatic colon cancer in Q2/Q3, 2017.

• Commencement of a Phase 1/2 trial of BNC105 in patients with Chronic Lymphocytic Leukaemia (CLL) in 1H, 2017.

The presentation will also highlight Bionomics' collaboration with Merck & Co (known as MSD outside the US and Canada) in cognition.

Meetings held with investors and pharma companies during the week will encompass the entire Bionomics pipeline of drug candidates with the objective of advancing partnering and clinical development.

A copy of the presentation can be found on the Bionomics website www.bionomics.com.au

FOR FURTHER INFORMATION PLEASE CONTACT: Australia US

Monsoon Communications Stern IR, Inc.

Rudi Michelson Beth Del Giacco

[phone] [phone]

[e-mail] [e-mail]

About Bionomics Limited

Bionomics (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates focused on the treatment of serious central nervous system disorders and on the treatment of cancer. Bionomics' lead drug candidate BNC210, currently in Phase 2 for the treatment of generalized anxiety disorder and for post-traumatic stress disorder, is a novel, proprietary negative allosteric modulator of the alpha-7 (α7) nicotinic acetylcholine receptor. The Company is also developing BNC101, its lead humanized monoclonal antibody targeting a key receptor on cancer stem cells that is overexpressed in metastatic colorectal cancer, metastatic pancreatic cancer and many other solid tumours; BNC101 entered clinical trials in the first quarter of 2016. Bionomics has strategic partnerships with Merck & Co., Inc (known as MSD outside the United States and Canada) in pain and cognition.

www.bionomics.com.au

Factors Affecting Future Performance

This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this announcement that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' drug candidates (including BNC210 and BNC101), its licensing agreements with Merck & Co. and any milestone or royalty payments thereunder, drug discovery programs, ongoing and future clinical trials, and timing of the receipt of clinical data for our drug candidates are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including unexpected safety or efficacy data, unexpected side effects observed in clinical trials, risks related to our available funds or existing funding arrangements, our failure to introduce new drug candidates or platform technologies or obtain regulatory approvals in a timely manner or at all, regulatory changes, inability to protect our intellectual property, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantage, as well as other factors. Results of studies performed on our drug candidates and competitors' drugs and drug candidates may vary from those reported when tested

in different settings.

Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this announcement.